Silencing the YB-1 gene inhibits cell migration in gastric cancer in vitro

Anatomical Record

Volumn 296, Issue 6, 2013, Pages 891-898

  Guo, Tian Tian ^a   Yu, Ying Nan ^a   Cheong Yip, George Wai ^a   Matsumoto, Ken ^b   Bay, Boon Huat ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

Author keywords

Cell migration; Gastric cancer; Gene silencing; YB 1

Indexed keywords

MESSENGER RNA; SMALL INTERFERING RNA; Y BOX BINDING PROTEIN 1;

ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CYTOPLASM; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IN VITRO STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; WESTERN BLOTTING;

CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; GENE SILENCING; HUMANS; NEOPLASM INVASIVENESS; RNA, MESSENGER; STOMACH NEOPLASMS; Y-BOX-BINDING PROTEIN 1;

EID: 84878040352     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.22702     Document Type: Article

References (51)

1. Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dorken B, Royer HD. 1997. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 3:447-450.
2. Basaki Y, Hosoi F, Oda Y, Fotovati A, Maruyama Y, Oie S, Ono M, Izumi H, Kohno K, Sakai K, Shimoyama T, Nishio K, Kuwano M. 2007. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene 26:2736-2746.
3. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, Malvezzi M, La Vecchia C. 2009. Recent patterns in gastric cancer: a global overview. Int J Cancer 125:666-673.
4. Chambers AF, Groom AC, MacDonald IC. 2002. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563-572.
5. Chiaravalli AM, Klersy C, Vanoli A, Ferretti A, Capella C, Solcia E. 2012. Histotype-based prognostic classification of gastric cancer. World J Gastroenterol 18:896-904.
6. Cohen SB, Ma W, Valova VA, Algie M, Harfoot R, Woolley AG, Robinson PJ, Braithwaite AW. 2010. Genotoxic stress-induced nuclear localization of oncoprotein YB-1 in the absence of proteolytic processing. Oncogene 29:403-410.
7. Didier DK, Schiffenbauer J, Woulfe SL, Zacheis M, Schwartz BD. 1988. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. Proc Natl Acad Sci USA 85:7322-7326.
8. Eliseeva IA, Kim ER, Guryanov SG, Ovchinnikov LP, Lyabin DN. 2011. Y-box-binding protein 1 (YB-1) and its functions. Biochemistry (Mosc) 76:1402-1433.
9. Evdokimova V, Ruzanov P, Anglesio MS, Sorokin AV, Ovchinnikov LP, Buckley J, Triche TJ, Sonenberg N, Sorensen PH. 2006. Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species. Mol Cell Biol 26:277-292.
10. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, Sorokin A, Ovchinnikov LP, Davicioni E, Triche TJ, Sorensen PH. 2009. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 15:402-415.
11. Faury D, Nantel A, Dunn SE, Guiot MC, Haque T, Hauser P, Garami M, Bognar L, Hanzely Z, Liberski PP, Lopez-Aguilar E, Valera ET, Tone LG, Carret AS, Del Maestro RF, Gleave M, Montes JL, Pietsch T, Albrecht S, Jabado N. 2007. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 25:1196-1208.
12. Friedl P. 2004. Prespecification and plasticity: shifting mechanisms of cell migration. Curr Opin Cell Biol 16:14-23.
13. Fuyuhiro Y, Yashiro M, Noda S, Matsuoka J, Hasegawa T, Kato Y, Sawada T, Hirakawa K. 2012. Cancer-associated orthotopic myofibroblasts stimulates the motility of gastric carcinoma cells. Cancer Sci 103:797-805.
14. Garcia MJA, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ. 2007. Global cancer facts and figures 2007. Atlanta, GA: American Cancer Society.
15. Gigek CO, Chen ES, Calcagno DQ, Wisnieski F, Burbano RR, Smith MA. 2012. Epigenetic mechanisms in gastric cancer. Epigenomics 4:279-294.
16. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Ettinger S, Gleave ME, Nelson CC. 2004. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 59:337-349.
17. Guarino M, Tosoni A, Nebuloni M. 2009. Direct contribution of epithelium to organ fibrosis: epithelial-mesenchymal transition. Hum Pathol 40:1365-1376.
18. Huber MA, Kraut N, Beug H. 2005. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17:548-558.
19. Hulit J, Suyama K, Chung S, Keren R, Agiostratidou G, Shan W, Dong X, Williams TM, Lisanti MP, Knudsen K, Hazan RB. 2007. N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Res 67:3106-3116.
20. Inoue I, Matsumoto K, Yu Y, Bay BH. 2012. Surmounting chemoresistance by targeting the Y-box binding protein-1. Anat Rec (Hoboken) 295:215-222.
21. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin 61:69-90.
22. Jurchott K, Bergmann S, Stein U, Walther W, Janz M, Manni I, Piaggio G, Fietze E, Dietel M, Royer HD. 2003. YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem 278:27988-27996.
23. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. 2003. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 25:691-698.
24. Kohno K, Sato S, Uchiumi T, Takano H, Tanimura H, Miyazaki M, Matsuo K, Hidaka K, Kuwano M. 1992. Activation of the human multidrug resistance-1 (mdr1) gene promoter in response to inhibitors of DNA topoisomerases. Int J Oncol 1:73-77.
25. Koike K, Uchiumi T, Ohga T, Toh S, Wada M, Kohno K, Kuwano M. 1997. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett 417:390-394.
26. Kotb AM, Hierholzer A, Kemler R. 2011. Replacement of E-cadherin by N-cadherin in the mammary gland leads to fibrocystic changes and tumor formation. Breast Cancer Res 13:R104.
27. Kuwano M, Oda Y, Izumi H, Yang SJ, Uchiumi T, Iwamoto Y, Toi M, Fujii T, Yamana H, Kinoshita H, Kamura T, Tsuneyoshi M, Yasumoto K, Kohno K. 2004. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther 3:1485-1492.
28. Li LH, Luo Q, Zheng MH, Pan C, Wu GY, Lu YZ, Feng B, Chen XH, Liu BY. 2012. P21-activated protein kinase 1 is overexpressed in gastric cancer and induces cancer metastasis. Oncol Rep 27:1435-1442.
29. Lin MT, Zuon CY, Chang CC, Chen ST, Chen CP, Lin BR, Wang MY, Jeng YM, Chang KJ, Lee PH, Chen WJ, Kuo ML. 2005. Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappaB/cyclooxygenase-2 signaling pathway. Clin Cancer Res 11:5809-5820.
30. Matsumoto K, Bay BH. 2005. Significance of the Y-box proteins in human cancers. J Mol Genet Med 1:11-17.
31. Matsumoto K, Wolffe AP. 1998. Gene regulation by Y-box proteins: coupling control of transcription and translation. Trends Cell Biol 8:318-323.
32. Moustakas A, Heldin CH. 2007. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 98:1512-1520.
33. Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ. 1999. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol 147:631-644.
34. Okamoto T, Izumi H, Imamura T, Takano H, Ise T, Uchiumi T, Kuwano M, Kohno K. 2000. Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression. Oncogene 19:6194-6202.
35. Park IK, Kim BJ, Goh YJ, Lyu MA, Park CG, Hwang ES, Kook YH. 1997. Co-expression of urokinase-type plasminogen activator and its receptor in human gastric-cancer cell lines correlates with their invasiveness and tumorigenicity. Int J Cancer 71:867-873.
36. Parkin DM. 2004. International variation. Oncogene 23:6329-6340.
37. Rathbone M, Rathbone B. 2011. Helicobacter pylori and gastric cancer. Recent Results Cancer Res 185:83-97.
38. Schittek B, Psenner K, Sauer B, Meier F, Iftner T, Garbe C. 2007. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer 120:2110-2118.
39. Shibao K, Takano H, Nakayama Y, Okazaki K, Nagata N, Izumi H, Uchiumi T, Kuwano M, Kohno K, Itoh H. 1999. Enhanced coexpression of YB-1 and DNA topoisomerase II alpha genes in human colorectal carcinomas. Int J Cancer 83:732-737.
40. Tay WL, Yip GW, Tan PH, Matsumoto K, Yeo R, Ng TP, Kumar SD, Tsujimoto M, Bay BH. 2009. Y-Box-binding protein-1 is a promising predictive marker of radioresistance and chemoradioresistance in nasopharyngeal cancer. Mod Pathol 22:282-290.
41. Thiery JP, Sleeman JP. 2006. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7:131-142.
42. Tran NL, Nagle RB, Cress AE, Heimark RL. 1999. N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion with stromal cells. Am J Pathol 155:787-798.
43. Uchiumi T, Kohno K, Tanimura H, Matsuo K, Sato S, Uchida Y, Kuwano M. 1993. Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation. Cell Growth Differ 4:147-157.
44. Voulgari A, Pintzas A. 2009. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 1796:75-90.
45. Wachowiak R, Thieltges S, Rawnaq T, Kaifi JT, Fiegel H, Metzger R, Quaas A, Mertens PR, Till H, Izbicki JR. 2010. Y-box-binding protein-1 is a potential novel tumour marker for neuroblastoma. Anticancer Res 30:1239-1242.
46. Wang J, Zhang J, Wu J, Luo D, Su K, Shi W, Liu J, Tian Y, Wei L. 2011. MicroRNA-610 inhibits the migration and invasion of gastric cancer cells by suppressing the expression of vasodilator-stimulated phosphoprotein. Eur J Cancer 48:1904-1913.
47. Woolley AG, Algie M, Samuel W, Harfoot R, Wiles A, Hung NA, Tan PH, Hains P, Valova VA, Huschtscha L, Royds JA, Perez D, Yoon HS, Cohen SB, Robinson PJ, Bay BH, Lasham A, Braithwaite AW. 2011. Prognostic association of YB-1 expression in breast cancers: a matter of antibody. PLoS One 6:e20603.
48. Wu Y, Yamada S, Izumi H, Li Z, Shimajiri S, Wang KY, Liu YP, Kohno K, Sasaguri Y. 2012. Strong YB-1 expression is associated with liver metastasis progression and predicts shorter disease-free survival in advanced gastric cancer. J Surg Oncol 105:724-730.
49. Yu YN, Yip GW, Tan PH, Thike AA, Matsumoto K, Tsujimoto M, Bay BH. 2010. Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle. Int J Oncol 37:483-492.
50. Zheng B, Liang L, Huang S, Zha R, Liu L, Jia D, Tian Q, Wang Q, Wang C, Long Z, Zhou Y, Cao X, Du C, Shi Y, He X. 2012. MicroRNA-409 suppresses tumour cell invasion and metastasis by directly targeting radixin in gastric cancers. Oncogene 31:4509-4516.
51. Zheng B, Liang L, Wang C, Huang S, Cao X, Zha R, Liu L, Jia D, Tian Q, Wu J, Ye Y, Wang Q, Long Z, Zhou Y, Du C, He X, Shi Y. 2011. MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res 17:7574-7583.